Sanara MedTech Q3 EPS $(0.13) Up From $(0.18) YoY, Sales $16.02M Miss $18.80M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sanara MedTech reported a narrower Q3 loss of $(0.13) per share compared to $(0.18) YoY, but missed sales estimates with $16.02M versus the expected $18.80M. Despite the miss, sales increased by 22.81% from the same period last year.
November 13, 2023 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sanara MedTech's Q3 EPS improved to $(0.13) from $(0.18) YoY, but sales of $16.02M missed estimates by 14.79%, despite a 22.81% increase from last year.
While the improvement in EPS is positive, the miss on sales estimates could concern investors. The growth in sales YoY is a good sign, but failing to meet analyst expectations may lead to short-term negative sentiment. The score is neutral as the positive EPS might offset the negative impact of the sales miss.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100